{"symbol": "PLX", "name": "Protalix BioTherapeutics, Inc.", "next_earnings_utc": 1591008600, "next_earnings_period_start_date_utc": 1577750400, "next_earnings_period_end_date_utc": 1585612800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": null, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -0.3, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 1, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "protalix.com", "year_founded": 1993, "street_address": "2 Snunit Street", "city": "Karmiel", "state": null, "zipcode": "2161401", "country": "Israel", "phone_number": "972 4 988 9488", "short_description": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally.", "long_description": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundacao Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NYSEMKT", "equity_type": "stocks", "market_cap": 115171357, "total_enterprise": 158304357, "number_of_employees": 196, "outstanding_shares": 32442636, "eps": -1.231684, "diluted_eps": -1.231684, "earnings_from_cont_operations": -18276000, "gross_profit": 43798000, "cash": 17792000, "total_debt": 60925000, "total_revenue": 54693000, "cash_from_operations": -19358000, "net_income": -18276000, "ebitda": -9100000, "year_low_stock_price": 1.7, "year_high_stock_price": 5.19, "stocktwits_watchlist_count": 12538, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/PLX.png"}